Stockreport

Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma

Revolution Medicines, Inc.  (RVMD) 
PDF Encouraging progression-free survival and overall survival profile Safety findings consistent with previously reported data, no new safety signals observed Investor we [Read more]